Protein-Protein Docking Studies on Magnesium Chelatase of Ulva fasciata Against the Human TSHR Protein

Abstract

The course and prognosis of hypothyroidism in humans are affected by the most common mutation in the hypothyroid protein, TSHR. To facilitate the potential mutant TSHR's interaction with Ulva fasciata's magnesium-chelatase, we utilize 3D Insilico drug docking approaches. The purpose of the entire research work is to introduce the seaweed protein against the humanTSHR protein using Insilico protocols. The translated amino acid sequence and three-dimensional chemical compound were taken from the NCBI database to perform drug docking procedures. In post-docking tests, advanced 3D molecular visualization capabilities were utilized. In post-docking tests, advanced 3D molecular visualization capabilities were utilized. The findings of the docking investigation indisputably demonstrate that amino acid mutational sites are directly suppressed by magnesium chelatase. The H-bond interaction between TSHR and magnesium chelatase is shown in three dimensions utilizing concepts from molecular dynamics techniques. Ultimately, we found that Ulva fasciata's pharmaceutical ingredient, magnesium chelatase, aids in the treatment of hypothyroidism. Hence, we finally conclude that one of the main endocrine hormonal problems is hypothyroidism, and our research serves to demonstrate how well the seaweed Ulva fasciata works as a unique medicinal agent to treat this disorder.